🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Entero Healthcare Solutions Limited ENTERO NSEPHARMA

Healthcare · Medical Distribution · India
https://www.enterohealthcare.com
Company Profile ↓
₹1,233.80
-0.64% 1Y
Mkt Cap₹5,368.38 Cr
P/E56.70
P/B3.20
52W High₹1,354.40
52W Low₹949.20
Book Value₹388.09
EPS (TTM)₹21.76

Company Overview

Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India. The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics. It also provides nebulizers, personal protective, hygiene and surgical consumable products, homecare medical devices, gloves and mobility equipment, digital thermometers. In addition, the company offers healthcare products, including pharmaceutical and nutraceutical products, vaccines, medical devices, such as orthopaedic implants and coronary stents, and hospital consumables comprising examination and surgical gloves, syringes, needles and sutures to hospitals, retail pharmacies, healthcare product manufacturers, and healthcare clinics. Entero Healthcare Solutions Limited was incorporated in 2018 and is based in Mumbai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 365.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 26.0% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹6,591.21 Cr (+29.3% YoY); net profit ₹115.04 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +29.3%, earnings +21.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 26.0%, profit CAGR 365.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:26.02%
1 Year:29.35%

Compounded Profit Growth

5 Years:365.14%
1 Year:21.33%

Stock Price Performance

1 Year:-0.64%
6 Months:+5.76%
3 Months:+0.24%
1 Month:+9.93%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 70% of range
₹949.20 ₹1,354.40
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)59.58 · Neutral
Price Performance
1M+9.93%
3M+0.24%
6M+5.76%
1Y-0.64%
Valuation vs Sector

P/E of 56.70 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 26.0% over 5 years.
  • Profit CAGR of 365.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 56.7.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
56.70
Industry PE
39.97
Forward P/E
22.38
PEG Ratio
-
Book Value
₹388.09
Price to Book
3.20
P/S
0.82
EV/EBITDA
22.00
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
26.02%
Profit 5Y
365.14%
Revenue (YoY)
29.35%
Earnings (YoY)
21.33%

Profitability & Returns

ROCE
11.61%
ROE
6.81%
ROA
3.20%
Profit Margin
1.75%
Op Margin
3.38%
Gross Margin
10.32%
EPS (Latest Qtr)
₹6.43
EPS (TTM)
₹21.76

Balance Sheet & Liquidity

Debt/Equity
0.40
Quick Ratio
1.05
Current Ratio
1.58
Debt
₹677.15 Cr
Total Assets
₹3,600.26 Cr
Current Assets
₹2,508.44 Cr
Working Capital
₹920.87 Cr

Ownership

Promoter Holding
65.92%
Chg in Prom Hold
-1.04%
FII / Inst Holding
14.82%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
₹5,368.38 Cr
Total Revenue (TTM)
₹6,591.21 Cr
EBITDA
₹277.01 Cr
Free Cash Flow
₹28.66 Cr
Operating Cash Flow
₹96.20 Cr
Shares Outstanding
₹4.35 Cr
Gross Margin
10.32%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ENTERO Entero Healthcare Solutions Limited NSEPHARMA 1,233.80 56.70 ₹5,368.38 Cr 0.00% 11.61% 6.81% 26.02% 365.14%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 887.00 Cr899.00 Cr996.00 Cr993.00 Cr1,034.00 Cr1,097.00 Cr1,301.00 Cr-1,339.06 Cr1,403.82 Cr1,570.95 Cr1,706.52 Cr1,909.93 Cr
Cost of Revenue --------1,208.29 Cr1,264.25 Cr1,410.15 Cr1,533.93 Cr1,702.51 Cr
Gross Profit --------130.77 Cr139.57 Cr160.80 Cr172.59 Cr207.42 Cr
Operating Expenses 867.00 Cr873.00 Cr968.00 Cr964.00 Cr1,005.00 Cr1,067.00 Cr1,258.00 Cr-90.35 Cr98.37 Cr108.57 Cr114.62 Cr136.17 Cr
Operating Income 13.00 Cr20.00 Cr23.00 Cr23.00 Cr22.00 Cr23.00 Cr35.00 Cr-40.42 Cr41.20 Cr52.23 Cr57.98 Cr71.25 Cr
EBITDA 20.00 Cr26.00 Cr29.00 Cr29.00 Cr29.00 Cr30.00 Cr42.00 Cr-56.21 Cr55.90 Cr66.86 Cr64.21 Cr90.05 Cr
Interest Expense 13.00 Cr14.00 Cr18.00 Cr16.00 Cr17.00 Cr10.00 Cr11.00 Cr-10.49 Cr10.66 Cr12.40 Cr14.01 Cr17.31 Cr
Pretax Income 1.00 Cr7.00 Cr7.00 Cr8.00 Cr14.00 Cr27.00 Cr35.00 Cr-37.23 Cr36.36 Cr44.62 Cr40.40 Cr57.95 Cr
Tax Provision 4.90 Cr42.00 L1.61 Cr1.28 Cr-7.84 Cr6.75 Cr8.75 Cr-5.80 Cr6.13 Cr8.03 Cr6.52 Cr12.82 Cr
Net Income -4.00 Cr6.00 Cr5.00 Cr7.00 Cr21.00 Cr21.00 Cr26.00 Cr-25.69 Cr27.80 Cr31.60 Cr27.63 Cr28.01 Cr
Diluted EPS -9.0515.183.194.224.824.625.43-5.906.387.256.346.43

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,350.00 Cr1,773.00 Cr-3,293.14 Cr3,888.16 Cr5,095.78 Cr6,591.21 Cr
Cost of Revenue ---3,031.86 Cr3,570.35 Cr4,609.47 Cr5,910.83 Cr
Gross Profit ---261.28 Cr317.81 Cr486.31 Cr680.38 Cr
Operating Expenses 1,326.00 Cr1,758.00 Cr-221.51 Cr230.98 Cr345.45 Cr457.72 Cr
Operating Income 11.00 Cr-1.00 Cr-39.77 Cr86.83 Cr140.86 Cr222.66 Cr
EBITDA 23.00 Cr15.00 Cr-64.95 Cr121.05 Cr211.05 Cr277.01 Cr
Interest Expense 13.00 Cr20.00 Cr-44.40 Cr60.48 Cr41.62 Cr54.38 Cr
Pretax Income 4.00 Cr-11.00 Cr--3.69 Cr35.55 Cr138.74 Cr179.34 Cr
Tax Provision 2.68 Cr-4.62 Cr-7.42 Cr-4.24 Cr31.30 Cr33.50 Cr
Net Income 1.00 Cr-15.00 Cr--11.56 Cr39.11 Cr94.82 Cr115.04 Cr
Diluted EPS 93.81-1,550.90-6.88-2.6610.8121.76-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 749.00 Cr836.00 Cr-1,308.73 Cr2,344.97 Cr2,702.51 Cr3,600.26 Cr
Current Assets ---1,023.17 Cr2,010.97 Cr2,075.71 Cr2,508.44 Cr
Cash & Equivalents ---25.36 Cr147.65 Cr229.28 Cr146.88 Cr
Inventory ---341.63 Cr421.15 Cr659.78 Cr841.68 Cr
Receivables ---514.88 Cr615.40 Cr830.36 Cr1,212.44 Cr
Total Liabilities ---711.07 Cr703.59 Cr932.16 Cr1,847.72 Cr
Current Liabilities ---623.96 Cr601.94 Cr845.02 Cr1,587.57 Cr
Long Term Debt ---31.07 Cr45.54 Cr0122.56 Cr
Total Debt 603.00 Cr720.00 Cr-437.76 Cr337.97 Cr385.23 Cr677.15 Cr
Total Equity -15.90 Cr-31.90 Cr-595.03 Cr1,638.06 Cr1,724.14 Cr1,688.61 Cr
Shares Outstanding ---4.35 Cr4.35 Cr4.35 Cr4.35 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -37.00 Cr-69.00 Cr--45.31 Cr-36.61 Cr-76.86 Cr96.20 Cr
Investing Cash Flow -203.00 Cr-31.00 Cr--48.59 Cr-705.12 Cr219.80 Cr-303.06 Cr
Financing Cash Flow 217.00 Cr89.00 Cr-72.76 Cr862.94 Cr-73.66 Cr123.66 Cr
Capital Expenditure -44.00 Cr-9.00 Cr--5.52 Cr-5.42 Cr-11.31 Cr-67.54 Cr
Free Cash Flow -81.00 Cr-78.00 Cr--50.83 Cr-42.03 Cr-88.18 Cr28.66 Cr
Net Change in Cash -23.00 Cr-11.00 Cr--21.15 Cr121.21 Cr69.28 Cr-83.20 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---7.9%8.2%9.5%10.3%
Operating Margin % 0.8%-0.1%-1.2%2.2%2.8%3.4%
Net Margin % 0.1%-0.8%--0.4%1.0%1.9%1.7%
ROE % -6.3%47.0%--1.9%2.4%5.5%6.8%
ROCE % ---5.8%5.0%7.6%11.1%

Shareholding Pattern

Insiders
65.92%
Institutions
14.82%
Public Float
43.49%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ENTERO

Google News Mon, 13 Jul 2026

Entero Healthcare Solutions director Rajesh Dalal steps down - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNcEpZU0FSOVIxOGZ5a2VBaUpPc1ZwLVNCY3ZKbzNHeTNKQ21zTlZfZUE3dE5RclFjbmV1MWlFNGE2WWlFRWFMQkVLRG1TNzUwM05yaXZ5ME9zVm95dVJVV1A3alQ0MWxtcEJ1Rlk2NGowdFgxaWNRZDhTZmQ4Z3pHc1I2VHcyOUdIeXJBbn…

Google News hu, 28 May 2026

Entero Healthcare Solutions Limited Just Missed Earnings - But Analysts Have Updated Their Models - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPdTJyeTRyNm1fcFoyR2ZWNE5BVy1ULUZzUC1Ja09FM216TGt0VVkxVkZjd1U5UTg2Y0FyZXlOeklmSjVmaHAxUElpWVlrb0lEcml1T0xYOGs4c284ZXdkSHVNczBvUGhWUDZSQXRmbE1QRE0tbExGVFhYT2ozZVJ1TzVDeVJCZnNaQWNSNU…

Google News Wed, 27 May 2026

Entero Healthcare Gets Target Price Hike On Strong Q4 Earnings As Jefferies Eyes 17% Upside - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPUW9tZEw2b1AxMTFLTmI2QjR6Q0lHM1lzc1VVTHhtWF9KNUREcEUxWUNqamNhR3hERzhnRWNXU3Y5LWoySVNpaGNkN20wTmJIY0M0UkNadTR1N1FuSExzOFVtcm96WnRUb3IzX092emtEbkRmb3FBbWw3a3hFMFNCcjFtOHUtU1Uya1JTY1…

Google News ue, 26 May 2026

Entero Health Standalone March 2026 Net Sales at Rs 78.93 crore, up 9.17% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQa1d6ckxtTUN3VFFFX1cxTGIzREpxb0dHRW41VkstUEs2VzVYc2p3S21rVHViLVBGWnNWT1owNVZEMGRXQWQ4a2ZJX0lnanNvMkdzemVUTXhoYUVfalA5ZzI0YWs5QmhucElFbzY1OUtjSXJBNlJvNU1zT1RBS0o5bnN4SWhPbE96SkZKcT…

Google News ue, 23 Jun 2026

Entero Healthcare closes trading window from July 1 until Q1FY27 results - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNSy1nalplX2g0VXhYVG5pZzI5eHB0MkdPTlprSmw0Xy1pUjJ2NFdmTGJKQmkzVS1QbWlOeHdnS0NRX09oNXNjLXVlM1V1V2UyVF9zV0hiZjVKR2M3TzNveElETHgyYUVPSHJVWGVOcTRucG1wUURsczJlMGJYQWFVSG9lT05QOVdiRVF5Zy…

Google News ue, 26 May 2026

Entero Health Consolidated March 2026 Net Sales at Rs 1,909.93 crore, up 42.63% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxOT0NvODBXMFNZTWRIR2puR1FnQmJjODdSMjdVc0xuWHlneUpxdUFtb0prTkRhci1lN1hpVGM4UnZzdEVpTGEtNUtaZENNc2J6NlFrS0NvbVZJOVJoaEVqc2otdW8tNVRDdHlZczk3dVVycHNjRkhsTWtIeGkxZ2NEbGdVOGdFUXN2V0daSj…

ENTERO — Frequently Asked Questions

What is the current share price of Entero Healthcare Solutions Limited (ENTERO)?

As of 2026-07-15 09:52 IST, Entero Healthcare Solutions Limited (ENTERO) trades at ₹1,233.80 on NSE. Its 52-week range is ₹949.20 to ₹1,354.40.

What is the market capitalisation of ENTERO?

Entero Healthcare Solutions Limited (ENTERO) has a market capitalisation of ₹5,368.38 Cr on NSE.

What is the P/E ratio of ENTERO?

ENTERO trades at a trailing price-to-earnings (P/E) ratio of 56.70. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.20.

What is the return on equity (ROE) of ENTERO?

ENTERO has a return on equity (ROE) of 6.81%. Its return on capital employed (ROCE) is 11.61%.

Is ENTERO a good stock to buy?

This page provides a data-driven analysis of Entero Healthcare Solutions Limited (ENTERO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space